Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$349.92 USD

349.92
440,220

+1.44 (0.41%)

Updated Aug 26, 2026 04:02 PM ET

After-Market: $349.92 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (71 out of 247)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

by Zacks Equity Research

WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.

Zacks Equity Research

Reasons to Retain Avanos Medical Stock in Your Portfolio Now

by Zacks Equity Research

AVNS's solid Q2 performance, strong product demand, and strategic transformation support growth amid tariff and FX headwinds.

Zacks Equity Research

Dentsply Sirona Retains Wellspect Following Strategic Review

by Zacks Equity Research

XRAY will keep its Wellspect unit, betting on its strong cash flows and $2B market to deliver greater long-term shareholder value.

Zacks Equity Research

Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System

by Zacks Equity Research

MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.

Zacks Equity Research

Lifeward Achieves European Approval for Latest ReWalk Exoskeleton

by Zacks Equity Research

LFWD secures CE mark for its ReWalk 7 Personal Exoskeleton, unlocking new European sales potential with advanced features.

Zacks Equity Research

Cardinal Health Expands At-Home Solutions With New Texas Facility

by Zacks Equity Research

CAH announces the opening of a new distribution center in Texas, which is likely to support its at-Home Solutions business.

Zacks Equity Research

GEHC Stock Gains Following Launch of Revolution Vibe CT Imaging System

by Zacks Equity Research

GE HealthCare's FDA-cleared Revolution Vibe CT promises faster, AI-driven cardiac imaging with improved clarity, boosting efficiency and patient comfort.

Zacks Equity Research

PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq

by Zacks Equity Research

PacBio collaborates with EpiCypher to integrate Fiber-Seq and HiFi sequencing, advancing single-molecule epigenomics with new chromatin mapping tools.

Zacks Equity Research

Here's Why You Should Hold Cencora Stock in Your Portfolio Now

by Zacks Equity Research

COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.

Zacks Equity Research

Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

by Zacks Equity Research

ECL's strong Q2 results, innovation pipeline, and high-tech growth drivers support its long-term expansion despite macro headwinds.